The company processes the majority of its internally developed Oncotype tests for domestic and international patients at its CLIA-certified and CAP-accredited clinical reference laboratory facilities in Redwood City, California. Since 2022, Oncotype DX Breast Recurrence Score tests for German patients have been processed at a newly constructed facility in Trier, Germany, partially operated by a third-party partner. Additional tests, including OncoExTra, immunohistochemistry, Oncodetect, and certain reference lab agreement tests, are processed at CLIA-certified and CAP-accredited clinical reference laboratory facilities in Phoenix, Arizona. Predefined genetic tests, custom panels, comprehensive germline whole exome and whole genome sequencing tests, and the hereditary cancer test Riskguard are processed at a CLIA-certified and CAP-accredited DNA testing laboratory in Marshfield, Wisconsin. The company states it currently has sufficient capacity to process all tests for at least the next 12 months and is expanding existing facilities to accommodate future growth.
Exact Sciences's Comment on Supply Chain
The company processes the majority of its internally developed Oncotype tests for domestic and international patients at its CLIA-certified and CAP-accredited clinical reference laboratory facilities in Redwood City, California. Since 2022, Oncotype DX Breast Recurrence Score tests for German patients have been processed at a newly constructed facility in Trier, Germany, partially operated by a third-party partner. Additional tests, including OncoExTra, immunohistochemistry, Oncodetect, and certain reference lab agreement tests, are processed at CLIA-certified and CAP-accredited clinical reference laboratory facilities in Phoenix, Arizona. Predefined genetic tests, custom panels, comprehensive germline whole exome and whole genome sequencing tests, and the hereditary cancer test Riskguard are processed at a CLIA-certified and CAP-accredited DNA testing laboratory in Marshfield, Wisconsin. The company states it currently has sufficient capacity to process all tests for at least the next 12 months and is expanding existing facilities to accommodate future growth.
Sources:
Exact Sciences Corporation's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Exact Sciences Corporation’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
